Stockreport

BBOT Announces First Patient Dosed with BBO-11818, a PanKRAS Dual Inhibitor, in the Phase 1 KONQUER-101 Trial for Advanced Solid Tumors

BridgeBio Pharma, Inc.  (BBIO) 
Last bridgebio pharma, inc. earnings: 3/2 08:29 am Check Earnings Report
PDF The first patient has been dosed with BBO-11818 in the KONQUER-101 first-in-human clinical studyBBO-11818 is an orally bioavailable small molecule panKRAS dual (“ON” and [Read more]